高级搜索

EP方案同步放疗治疗局限期小细胞肺癌的临床研究

The Study of Concurrent Chemoradiation with EP Regimen in Limited Stage Small Cell Lung Cancer

  • 摘要: 目的 研究EP方案同步放疗治疗42例局限期小细胞肺癌的疗效及副反应。方法 化疗采用EP方案:放疗为常规分割2Gy/次,每周5次,总剂量为54-60Gy。结果 治疗过程中放射性肺炎发生率62%,其中Ⅲ级为7%;急性放射性食管炎发生率为79%,Ⅲ~Ⅳ级为12%;粒细胞下降发生率为71%,Ⅲ~Ⅳ级为21%;中位生存期为23月,1、2、3年局部控制率分别为88%、79%、71%;1、2、3年生存率分别为86%、55%、24%。结论 EP方案同步放疗治疗局限期小细胞肺癌,患者可耐受,局部控制率和生存率有所改善,长期生存优势有待进一步观察。

     

    Abstract: Objective  To investigate the outcomes and toxicities in 42 patients with limited stage small cell lung cancer (SCLC) treated with concurrent chemoradiothery. Methods  The patients received EP regimen. Cisplatin (DDP) was administ rated with 25mg. m- 2, d1 - 3 ; Etop side (VP - 16) 100mg. m- 2, d1- 3, repeated every 21 days for 4 - 6 cycles. Irradiation was performed in conventional f raction (2 Gy per fraction per day, 5 days in a week) with total dose (DT) 54~60 Gy. Results  The acute toxicities included the incidence of radiation pneumotitis was 62 %, Total and grade 3 or 4 radiation esophagititis rates were 79 % and 12 % respectively. And grade 3 or 4 neut ropenia was 21 %. The 1 - year, 2 - year, 3 - year local cont rol rate and overall survival rate were 88 %, 79 %, 71 % and 86 %, 55 %, 24 % respectively. Conclusion  Concurrent chemoradiation with EP regimen in limited stage SCLC patient s is acceptable. Both local cont rol rate and overall survival rate are improved. The late toxicities and longer overall survival need further follow - up.

     

/

返回文章
返回